Stephen A. Sherwin, MD, currently divides his time between advisory work in the life science industry, and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. In his advisory work, Dr. Sherwin serves as a director of Aduro Biotech, Biogen, Neurocrine Biosciences, and Rigel Pharmaceuticals and as a venture partner at Third Rock Ventures. He is also a member of the scientific steering committee of the Parker Institute for Cancer Immunotherapy.
Previously Dr. Sherwin was chairman and chief executive officer of Cell Genesys, a cancer immunotherapy company, from 1990 until the company’s merger in 2009 with BioSante Pharmaceuticals (now ANI Pharmaceuticals). He was also co-founder and chairman of Abgenix, an antibody company which was acquired by Amgen in 2006, and co-founder and chairman of Ceregene, a gene therapy company which was acquired by Sangamo Biosciences in 2013. From 1983 to 1990, Dr. Sherwin held various positions in clinical research at Genentech, most recently that of vice president, and prior to 1983, he was on the staff of the National Cancer Institute. In addition, Dr. Sherwin previously served on the board of directors of the Biotechnology Industry Organization from 2001 to 2014 and as its chairman from 2009 to 2011, and was a member of the President’s Council of Advisors in Science and Technology (PCAST) Working Group on Drug Development from 2011 to 2013.
Dr. Sherwin holds a bachelor’s degree in biology from Yale University, received his medical degree from Harvard Medical School, and is board-certified in internal medicine and medical oncology and a fellow of the American College of Physicians.